Monte Rosa Therapeutics to Participate in Piper Sandler 33rd Annual Virtual Healthcare Conference

Rhea-AI Summary

Monte Rosa Therapeutics, a biotechnology firm (NASDAQ: GLUE), will participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference from Nov. 30 to Dec. 2, 2021. The management team's pre-recorded fireside chat is accessible for registered attendees via the conference site from Nov. 22 to Dec. 2. Additionally, an archived version of the chat will be available on the company’s investor site in the “Events & Presentations” section. Monte Rosa is focused on developing molecular glue degrader medicines through its proprietary QuEEN™ platform, leveraging advanced technologies for protein degradation.

BOSTON, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader medicines, today announced members of its management team will be participating in the Piper Sandler 33rd Annual Virtual Healthcare Conference from Nov. 30-Dec. 2, 2021. The company’s pre-recorded fireside chat is available for registered attendees via the Piper Sandler conference site from Nov. 22-Dec. 2.

An archived webcast of the fireside chat can be accessed via the “Events & Presentations” section of the company’s investor site at https://ir.monterosatx.com/.

About Monte Rosa
Monte Rosa Therapeutics is a biotechnology company developing a portfolio of novel molecular glue degrader medicines. These medicines are designed to employ the body’s natural mechanisms to selectively eliminate therapeutically relevant proteins. The company has developed a proprietary protein degradation platform, called QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates), that enables it to rapidly identify protein targets and molecular glue degrader, or MGD, product candidates that are designed to eliminate therapeutically relevant proteins in a highly selective manner. The company’s drug discovery platform combines diverse and proprietary chemical libraries of small molecule protein degraders with in-house proteomics, structural biology, AI/machine learning-based target selection and computational chemistry capabilities to predict and obtain protein degradation profiles. For more information, visit www.monterosatx.com.

Contacts:

Investors
Michael Morabito, Solebury Trout
ir@monterosatx.com

Media
Dan Budwick, 1AB
dan@1abmedia.com

FAQ

What event will Monte Rosa Therapeutics participate in?

Monte Rosa Therapeutics will participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference from Nov. 30 to Dec. 2, 2021.

When can attendees access the pre-recorded fireside chat?

Registered attendees can access the pre-recorded fireside chat from Nov. 22 to Dec. 2, 2021.

Where can I find the archived webcast of Monte Rosa's fireside chat?

The archived webcast of Monte Rosa's fireside chat can be accessed in the 'Events & Presentations' section on their investor site.

What is the focus of Monte Rosa Therapeutics?

Monte Rosa Therapeutics focuses on developing novel molecular glue degrader medicines using its proprietary QuEEN™ platform.

What does the QuEEN™ platform do?

The QuEEN™ platform enables Monte Rosa to identify protein targets and develop molecular glue degrader product candidates that selectively eliminate therapeutically relevant proteins.